24-GI-135-AZ (D7025C00001): A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer with Curative Intent (ARTEMIDE

Grants and Contracts Details

StatusActive
Effective start/end date9/26/24 → 9/26/26

Funding

  • AstraZeneca Pharmaceuticals LP (domestic): $2.00